International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 5 , Pages 1376-1382 , 1 April 2009

Radiation Therapy Field Extent for Adjuvant Treatment of Axillary Metastases From Malignant Melanoma

  • Beth M. Beadle, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • B. Ashleigh Guadagnolo, M.D., M.P.H.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationReprint requests to: B. Ashleigh Guadagnolo, M.D., M.P.H., The University of Texas M. D. Anderson Cancer Center, Department of Radiation Oncology, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030. Tel: (713) 563-2300; Fax: (713) 563-2331
    • ,
  • Matthew T. Ballo, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Jeffrey E. Lee, M.D.

      Affiliations

    • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Jeffrey E. Gershenwald, M.D.

      Affiliations

    • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Janice N. Cormier, M.D., M.P.H.

      Affiliations

    • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Paul F. Mansfield, M.D.

      Affiliations

    • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Merrick I. Ross, M.D.

      Affiliations

    • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Gunar K. Zagars, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Received 30 April 2008 ,Revised 18 June 2008 ,Accepted 23 June 2008.

References 

  1. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20:1818–1825
  2. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  3. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370–2380
  4. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys. 1986;12:867–872
  5. Habermalz HJ, Fischer JJ. Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer. 1976;38:2258–2262
  6. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20:429–432
  7. Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am. 1996;76:1383–1398
  8. Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002;52:964–972
  9. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051–1055
  10. Byers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg. 1986;121:1338–1341
  11. Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2000;46:467–474
  12. O'Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162:310–314
  13. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker; 1991;
  14. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991;
  15. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971;31:830–833
  16. Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol. 1971;44:816–817
  17. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective Phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma—Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81:136–142
  18. Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer. 2000;88:88–94
  19. Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease?. Head Neck. 2005;27:718–721
  20. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park). 2004;18:99–107discussion 107–110, 113–104
  21. Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66:1051–1055

 Conflict of interest: none.

PII: S0360-3016(08)02942-8

doi: 10.1016/j.ijrobp.2008.06.1910

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 5 , Pages 1376-1382 , 1 April 2009

Article Tools

* Image Usage & Resolution